지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Drug allergy exhibits a wide range of clinical features that partly reflect the diversity of the underlying responsible mechanisms.
These range from non-immunologic idiosyncratic reactions to Gell and Coombs type 1, 2, 3, and 4 reactions. Consequently, a drugallergy may be difficult to differentiate from an adverse drug reaction. The prevalence of drug allergy varies but is assumed to accountfor 30% of all adverse drug reactions. In the U.S., 3.1-6.2% of all ward patients are admitted because of adverse drug reactions,and 5-10% of all out-patients or ward patients have suffered an adverse drug reaction. Nonsteroidal anti-inflammatorydrugs (NSAIDs), antibiotics, and radiocontrast media are the most common causes of drug allergy, but with the recent introductionof molecular anti-cancer agents, the number of drug allergy cases by these agents is soaring. Drug allergy is an important cause ofmortality in admitted patients, and 1 out of every 10,000 admitted patients will die because of a drug allergy. Approximately 30% ofadverse drug reactions can be prevented if previous reactions have been monitored and managed adequately. In 2006, a regionalpharmacovigilance program was launched in Korea. In addition, the Korean Institute of Drug Safety and Risk Management plans todevelop a nationwide drug utilization review program to monitor adverse drug reactions and to provide relevant information fromthe program to health professionals working in hospitals and clinics, with the aim of preventing drug allergies. Recent studies haveshown a strong association between human leukocyte antigen genotypes and the severe cutaneous adverse reactions (SCARs) inducedby certain drugs. Genotype prescreening may contribute to the prevention of SCARs induced by culprit drugs such as carbamazepine,allopurinol, and abacavir.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Bates DW / 1995 / Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention study group / JAMA 274 : 29 ~ 34
Borovicka JH / 2011 / Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents / Arch Dermatol 147 : 1403 ~ 1409
Brockow K / 2005 / Management of hypersensitivity reactions to iodinated contrast media / Allergy 60 : 150 ~ 158
Brown AF / 2001 / Emergency department anaphylaxis:a review of 142 patients in a single year / J Allergy Clin Immunol 108 : 861 ~ 866
Celik G / 2013 / Middletone’s Allergy:principles and practice / Elsevier Health Sciences : 1274 ~ 1295
Borovicka JH / 2011 / Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents / Arch Dermatol 147 : 1403 ~ 1409
Brockow K / 2005 / Management of hypersensitivity reactions to iodinated contrast media / Allergy 60 : 150 ~ 158
Brown AF / 2001 / Emergency department anaphylaxis:a review of 142 patients in a single year / J Allergy Clin Immunol 108 : 861 ~ 866
Celik G / 2013 / Middletone’s Allergy:principles and practice / Elsevier Health Sciences : 1274 ~ 1295
이 논문의 저자 정보
최근 본 자료
댓글(0)
0